Repligen Corporation (NASDAQ:RGEN) Stock Has Average Price Target of $178.57 According to Brokerages

Repligen Corporation (NASDAQ:RGEN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eighteen brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, twelve have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $178.57.

Several research analysts recently weighed in on RGEN shares. Wells Fargo & Company boosted their price objective on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. UBS Group reissued a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Barclays upped their price objective on shares of Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings cut Repligen from a “hold (c)” rating to a “sell (d+)” rating in a report on Monday, November 2nd.

Check Out Our Latest Stock Analysis on RGEN

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. American Century Companies Inc. increased its stake in Repligen by 13.3% in the third quarter. American Century Companies Inc. now owns 241,239 shares of the biotechnology company’s stock valued at $46,373,000 after acquiring an additional 28,235 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Repligen in the 3rd quarter valued at $360,000. Advisors Asset Management Inc. acquired a new stake in shares of Repligen in the 3rd quarter valued at $1,594,000. Castleark Management LLC bought a new position in shares of Repligen in the 3rd quarter valued at $10,907,000. Finally, Empowered Funds LLC bought a new stake in shares of Repligen during the 3rd quarter valued at approximately $8,982,000. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Repligen stock opened at $163.81 on Wednesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 8.43. The stock has a fifty day moving average price of $177.16 and a two-hundred day moving average price of $145.99. Repligen has a 52-week low of $100.99 and a 52-week high of $198.87. The firm has a market capitalization of $10.47 billion, a P/E ratio of 79.79, a P/E/G ratio of 2.79 and a beta of 1.11.

Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The firm had revenue of $209.31 million for the quarter, compared to analyst estimates of $206.70 million. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.46 earnings per share. As a group, analysts anticipate that Repligen will post 2.07 EPS for the current fiscal year.

Repligen Company Profile

(Get Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

Featured Articles

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.